TY - JOUR
T1 - Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin c as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy
AU - Benedetti Panici, P.
AU - Scambia, G.
AU - Greggi, S.
AU - Salerno, G.
AU - Cento, R.
AU - Mancuso, S.
PY - 1990
Y1 - 1990
N2 - Fourteen patients with advanced ovarian carcinoma (FIGO stages 111-IV) resistant to cisplatin were submitted to an alternating regimen with doxorubicin (A), cyclophosphamide (C), bleomycin (B) and mitomycin C (M). All patients had measurable disease on entry into the study. No responses were observed while 3 patients, previously showing no change in cisplatin, had disease stabilization lasting 3, 4 and 6 months, respectively. All but 1 patient died with a median survival from the start of ACBM therapy of 7 months (range 6-11). ACBM-induced toxicity was remarkable with 50% grade 11-111 myelotoxicity which required a dose reduction in 43%, treatment delays in 64% and treatment discontinuation in 14%. All patients suffered from mild to moderate nausea and vomiting while reversible alopecia was seen in 42.8%. The lack of response and the substantial toxicity observed suggest that the ACBM regimen in the doses and schedule employed is not phamide in combination with adriamycin [10]; (4) each drug has a somewhat different mechanism of action, pharmacology and pattern of therapeutic toxicity; (5) no drug has shown substantial neurotoxicity, and (6) the alternating administration of the drugs may reduce toxicity and increase the number of cycles that could be given.
AB - Fourteen patients with advanced ovarian carcinoma (FIGO stages 111-IV) resistant to cisplatin were submitted to an alternating regimen with doxorubicin (A), cyclophosphamide (C), bleomycin (B) and mitomycin C (M). All patients had measurable disease on entry into the study. No responses were observed while 3 patients, previously showing no change in cisplatin, had disease stabilization lasting 3, 4 and 6 months, respectively. All but 1 patient died with a median survival from the start of ACBM therapy of 7 months (range 6-11). ACBM-induced toxicity was remarkable with 50% grade 11-111 myelotoxicity which required a dose reduction in 43%, treatment delays in 64% and treatment discontinuation in 14%. All patients suffered from mild to moderate nausea and vomiting while reversible alopecia was seen in 42.8%. The lack of response and the substantial toxicity observed suggest that the ACBM regimen in the doses and schedule employed is not phamide in combination with adriamycin [10]; (4) each drug has a somewhat different mechanism of action, pharmacology and pattern of therapeutic toxicity; (5) no drug has shown substantial neurotoxicity, and (6) the alternating administration of the drugs may reduce toxicity and increase the number of cycles that could be given.
KW - Chemotherapy
KW - Cisplatin resistance
KW - Myelotoxicity
KW - Ovarian carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0025283309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025283309&partnerID=8YFLogxK
U2 - 10.1159/000226836
DO - 10.1159/000226836
M3 - Article
C2 - 1694980
AN - SCOPUS:0025283309
VL - 47
SP - 296
EP - 298
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 4
ER -